5d 1m 3m 1y 5y 10y
Business Wire (Fri, 12:15PM)
Business Wire (Tue, 9:34AM)
Business Wire (Mon, 8:15AM)
Business Wire (Feb 28, 2014)
at CNBC.com (Feb 27, 2014)
Business Wire (Feb 24, 2014)
Business Wire (Feb 24, 2014)
Business Wire (Feb 21, 2014)
at CNBC.com (Feb 18, 2014)
Business Wire (Feb 13, 2014)
at CNBC.com (Feb 6, 2014)
Business Wire (Feb 6, 2014)
at CNBC.com (Feb 5, 2014)
at CNBC.com (Jan 30, 2014)
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mLBusiness Wire (Jan 28, 2014)
at MarketWatch.com (Jan 21, 2014)
Marketwire (Jan 21, 2014)
Business Wire (Jan 21, 2014)
at CNBC.com (Jan 8, 2014)
at CNBC.com (Dec 30, 2013)
at CNBC.com (Dec 27, 2013)
at CNBC.com (Dec 27, 2013)
at CNBC.com (Dec 20, 2013)
TEVA vs. ETF Alternatives
Friday, Oct 252013, 10:05 AM
Friday, Oct 252013, 10:05 AM| 2 Comments
- Citi's Liav Abraham thinks the value in shares of Teva (TEVA +0.7%) can be unlocked if investors can manage to "look past the Copaxone cliff and focus on the growth profile of the company's ex-Copaxone franchises, which comprise 80% of the company's intrinsic value and are growing at a 19% 5-year CAGR."
- As mentioned earlier, the shares are initiated at Buy.
- Price target is $47, representing a 17% upside from Thursday's close.
Friday, Oct 252013, 9:26 AM
Friday, Oct 252013, 9:26 AM| 2 Comments
- The FDA is set to reclassify hydrocodone-based painkillers as Schedule II substances (up from Schedule III) to reflect their potential for abuse.
- What it means (practically speaking): Refills would be limited to a 90-day supply as opposed to 180 days.
- Companies that make either brand name or generic versions: AbbVie (ABBV), Actavis (ACT), Teva (TEVA), Mallinckrodt (MNK).
Friday, Oct 252013, 8:53 AM
Friday, Oct 252013, 8:53 AM| 1 Comment
- McKesson (MCK) upgraded to Overweight from Equalweight at Morgan Stanley.
- Shire (SHPG) upgraded to Buy from Neutral at BofA.
- Forest Labs (FRX) upgraded to Market Perform from Underperform at BMO. Price target hiked to $33 from $27.
- Citi initiates Mylan (MYL) at Neutral with a price target of $42.
- Citi starts Teva (TEVA) at Buy with a $47 price target.
- Citi starts Actavis (ACT) at Buy with a $172 price target.
Wednesday, Oct 162013, 3:30 PM
Wednesday, Oct 162013, 3:30 PM| 2 Comments
- "Teva (TEVA +0.9%) has grossly violated its contract with the state. It is demonstrating an utter lack of solidarity, commitment to society, and gratitude," Israeli opposition leader Shelly Yachimovich said at the opening of the winter parliamentary session.
- After facing intense pressure from labor and from the government, the company has put on hold a plan to cut jobs.
- Adding to the uproar is a report from the state comptroller which shows the company got years of preferential tax treatment that amounted to some $3.4B between 2006 and 2011.
- Summing up sentiment, here's Yachimovich again: "Layoffs at a company that pays almost zero taxes are an act of cannibalism. There is no other word."
Wednesday, Oct 162013, 10:50 AM
Monday, Oct 142013, 10:22 AM
Sunday, Oct 132013, 2:59 AM
Sunday, Oct 132013, 2:59 AM| Comment!
- California Governor Jerry Brown has vetoed a bill that would have limited the use of biosimilar pharmaceuticals in the state.
- Brown explained that the legislation was premature, as the FDA hasn't yet set the rules governing such drugs.
- Biosimilars are the copycat versions of biotech drugs - also known as biologics - which are complex proteins developed in living cells. Biosimilars are not called generics, as it's difficult to prove that they're exactly the same as the biologic original.
- The campaign to limit the use of biosimilars has been led by Amgen (AMGN) and Genentech (RHHBY.OB); so far, 10 states have blocked such efforts this year, including Illinois and Texas.
- Companies developing biosimilars include Hospira (HSP), Novartis (NVS), Momenta Pharmaceuticals (MNTA), Baxter (BAX) and Teva (TEVA).
- Healthcare ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS
Thursday, Oct 102013, 7:30 AM
Thursday, Oct 102013, 7:30 AM| Comment!
- Teva (TEVA) intends to cut 5,000 jobs - or 10% of its total workforce - as part of a plan to accelerate its cost-reduction program, which it introduced in December.
- Teva expects to generate $2B in annual cost savings by the end of 2017, including $1B by the end of 2014.
- Plans to continue trimming "assets that no longer fit its core business or are not critical to its future."
- Estimates pre-tax costs for the restructuring at $1.1B.
- However, Teva still intends to invest in R&D and Sales & Marketing for "high-potential programs."
- Shares +1% premarket. (PR)
Friday, Oct 42013, 7:54 AM
Friday, Oct 42013, 7:54 AM| Comment!
- Teva (TEVA) scores a favorable court ruling in the Netherlands, as a District Court of the Hague rejects the grounds of invalidity Mylan (MYL) raised against a European Copaxone patent.
- Generic versions of the RRMS drug "would require a marketing authorization from the Netherlands Medicines Evaluation Board," TEVA notes, adding that the complexity of the drug opens the door for "unpredictable differences between a proposed generic product and Copaxone [which could] lead to immunogenic effects in patients." (PR)
Friday, Oct 42013, 7:22 AM
Friday, Oct 42013, 7:22 AM| Comment!
- Biogen Idec's (BIIB) Tecfidera multiple sclerosis treatment was effective in patients for at least four years in two long-term studies.
- Tecfidera lowered disease activity as measured by relapses and the progression of MS in patients, with subjects experiencing a low frequency of new MS brain lesions.
- There were also no new safety issues, with no increased risk of serious infections, cancers, kidney dysfunction or liver problems.
- Tecfidera is expected to dominate the MS market and clocked up sales of $192M in Q1.
- Biogen shares appear to be inactive premarket, as are those of rival Teva (TEVA). (PR)
Tuesday, Sep 242013, 7:05 AM|Tuesday, Sep 242013, 7:05 AM| Comment!
Monday, Sep 232013, 9:46 AM
Monday, Sep 232013, 9:46 AM| Comment!
- A U.S. District Court has upheld the validity of a Teva (TEVA +0.1%) patent that covers methods of treating Parkinson's disease and is related to the company's Azilect treatment.
- The ruling came after Teva sued Mylan (MYL -1.5%) for infringing the IP, and the Israeli company expects the court to prevent Mylan from launching its generic version of Azilect until Teva's patent expires in 2017.
- Teva has also filed a lawsuit suit against Sandoz, which has agreed to abide by the verdict in the case against Mylan. (PR)
Friday, Sep 202013, 2:45 PM
Tuesday, Sep 172013, 9:32 AM
Monday, Sep 162013, 1:19 PM
Monday, Sep 162013, 10:29 AM
Monday, Sep 162013, 10:29 AM| Comment!
- Teva (TEVA -0.4%) joins forces with Cancer Research Technology to research and develop DDR-modulating cancer drugs.
- The approach involves targeting cancer cells' ability to repair DNA damage caused by chemotherapy. Cancer Research UK's scientists are global leaders in the field, the company says.
- The deal will help TEVA "focus on personalized medicine throughout its R&D pipeline." (PR)
- CEO Jeremy Levin is in the midst of reshaping the company, and part of the process is a renewed focus on the research pipeline, although the real focal point of development efforts has generally been respiratory and central nervous system illnesses rather than oncology.